Noveris Health Sciences Becomes Member of Life Sciences BC to Strengthen Biotech Network in British Columbia

Noveris Health Sciences Formalizes Membership with Life Sciences British Columbia

Noveris Health Sciences Inc. confirmed on July 14, 2026, that it formally joined Life Sciences British Columbia, with membership effective as of July 13, 2026. The announcement, released via TheNewswire, highlights LSBC as a non-governmental, not-for-profit industry association dedicated to supporting and representing B.C.’s life sciences community through leadership, investment, advocacy, and promotion.

This move represents a strategic alignment by Noveris with one of Canada’s leading provincial platforms for life sciences connectivity. LSBC acts as a central network linking companies, academic institutions, researchers, and capital providers within British Columbia’s healthcare and biotech sectors. Noveris, trading on the Canadian Securities Exchange (NVRS), Frankfurt Stock Exchange (0NF0), and OTC market (MYCOF), plans to actively engage in LSBC events, programming, and sector initiatives.

Role of Life Sciences BC in British Columbia’s Biotech Sector

Life Sciences British Columbia is a non-profit, non-governmental organization tasked with strengthening the province’s life sciences ecosystem. LSBC offers member services, industry programming, networking opportunities, and initiatives aimed at fostering innovation and commercialisation within B.C.’s life sciences industry. The association connects private companies, research bodies, and investors, providing members with platforms to raise their profiles and build strategic partnerships.

British Columbia has become a significant hub for Canadian biotechnology and healthcare innovation, with LSBC recognized as the primary industry voice at the provincial level. For emerging biotech firms like Noveris, access to LSBC’s network and advocacy resources offers practical advantages in increasing visibility among potential collaborators and capital sources engaged with the association.

Strategic Intent Behind Noveris Joining LSBC

The company views its LSBC membership as a key tool to enhance its engagement within British Columbia’s life sciences ecosystem. Noveris expects the membership to improve its visibility locally and nationally, while providing access to networking, industry programs, and collaborative initiatives. This relationship-building is part of the company’s broader strategic development plan.

Joining an established industry association like LSBC can help a publicly traded biotech company raise awareness among sector stakeholders, facilitate introductions to potential licensing partners or investors, and position itself as a credible and active participant in healthcare innovation. The company did not disclose any financial terms or fees related to the LSBC membership.

CEO Jason Birmingham Highlights Importance of LSBC Membership

Jason Birmingham, President and CEO of Noveris, commented on the significance of joining LSBC: "Joining Life Sciences BC reflects our commitment to being an active participant in British Columbia's life sciences sector." He emphasized the value of aligning with organizations that unite scientific innovation, investment, advocacy, and commercialisation support, and expressed enthusiasm about contributing to and benefiting from the LSBC community as the company advances its strategic goals.

Birmingham’s remarks frame the membership as both an external commitment to sector involvement and an internal investment in Noveris’ development pipeline. His reference to advancing "strategic priorities" links the LSBC membership to the company’s wider operational agenda, although no specific milestones or product targets were mentioned.

Anticipated Advantages: Increased Visibility, Networking, and Commercialisation Opportunities

The announcement outlines expected benefits of LSBC membership for Noveris, including enhanced company profile within healthcare and biotech sectors, access to LSBC events and programming, knowledge-sharing opportunities, and the ability to build long-term strategic relationships with innovators, investors, advisors, and other stakeholders across British Columbia. The company anticipates that membership will foster collaboration and support commercialisation efforts.

Noveris views its participation in LSBC as an ongoing commitment rather than a one-off affiliation. Continued engagement with LSBC events and initiatives may help the company establish a sustained presence within B.C.’s life sciences community, reinforcing its profile among key stakeholders relevant to its commercialisation strategy. Investors may watch for tangible outcomes such as new partnerships, research collaborations, or capital raising linked to LSBC involvement.

Company Overview and Market Presence of Noveris Health Sciences

Noveris Health Sciences Inc. is a biotechnology firm focused on developing, advancing, and commercialising healthcare technologies addressing unmet market needs. Its common shares trade on the Canadian Securities Exchange (NVRS), Frankfurt Stock Exchange (0NF0), and OTC market (MYCOF). The company’s website is www.noveris.health.

The multi-exchange listing strategy aims to maintain visibility among North American and European investors. The announcement did not provide details on the company’s product pipeline, clinical development status, revenues, or financial position, focusing solely on the LSBC membership. Investors seeking comprehensive operational and financial information should consult the company’s latest regulatory filings on SEDAR+ or other official disclosure platforms.

Noveris’ Position Within British Columbia’s Life Sciences Ecosystem

British Columbia has emerged as a leading Canadian center for life sciences, hosting a growing cluster of biotech, medical device, digital health, and pharmaceutical companies around Vancouver. Industry associations like LSBC play a vital role by facilitating knowledge exchange, advocating for supportive policies, and connecting emerging firms with established players and capital networks.

For a company at Noveris’ stage, formal membership in LSBC signals active cultivation of relationships necessary for future commercialisation and growth. The announcement does not indicate any prior formal relationship between Noveris and LSBC or specify upcoming LSBC events Noveris plans to attend. No membership-related costs were disclosed.

Forward-Looking Statements and Disclosures

The release includes standard forward-looking statements disclaimers, noting that anticipated benefits of LSBC membership—such as increased visibility, collaboration, stakeholder engagement, event participation, and strategic support—are based on management’s current expectations as of the announcement date. Actual results may differ materially due to business, market, economic, regulatory changes, or the company’s ability to realize these benefits.

Noveris confirms it has no obligation to update forward-looking statements except as required by securities laws. The Canadian Securities Exchange has neither approved nor disapproved the news release content. Investors are advised to consider these disclaimers when evaluating the LSBC membership’s significance relative to Noveris’ strategic objectives.

Market Reaction and Share Price Impact

At the time of this report, the immediate impact on Noveris’ share price was unclear. The LSBC membership announcement is primarily a strategic and networking development rather than a financial transaction, product approval, or revenue event, so near-term market response may be limited.

Investors may interpret this announcement as part of broader corporate positioning, reflecting management’s approach to building sector relationships and advancing commercialisation. Noveris shares remain accessible on the CSE (NVRS), FSE (0NF0), and OTC (MYCOF) for those monitoring the company’s progress in biotechnology.